A Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension

References

• Galie N, Humbert M, Vachiery L, et al; 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2015. doi:10.1093/eurheartj/ehv317
   Web of Science ®Google Scholar
• Rose-Jones LJ, McLaughlin VV. Pulmonary hypertension: types and treatments. Curr Cardiol Rev. 2015;11(1):73–79. doi:10.2174/1573403X09666131117164122
   PubMedGoogle Scholar
• Hoeper MM, Ghofrani HA, Grunig E, Klose H, Olschewski H, Rosenkranz S. Pulmonary hypertension. Dtsch Arztebl Int. 2017;114:73–84. doi:10.3238/arztebl.2017.0073
   PubMed Web of Science ®Google Scholar
• Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):1–12. doi:10.1177/2045894020977300
   Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618–3731. doi:10.1093/eurheartj/ehac237
   PubMed Web of Science ®Google Scholar
• Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2018. doi:10.1183/13993003.01889
   Google Scholar
• Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D92–D99. doi:10.1016/j.jacc.2013.10.024
   PubMed Web of Science ®Google Scholar
• Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141(3):702–710. doi:10.1016/j.jtcvs.2010.11.024
   PubMed Web of Science ®Google Scholar
• Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2700 patients. Ann Thorac Surg. 2012;94(1):97–103. doi:10.1016/j.athoracsur.2012.04.004
   PubMed Web of Science ®Google Scholar
• NHS Royal Papworth Hospital. Pulmonary endarterectomy service. NHS Royal Papworth Hospital; 2021. Available from: https://royalpapworth.nhs.uk/our-services/surgery/pulmonary-endarterectomy-service. Accessed August 1, 2023.
   Google Scholar
• Ishida K, Masuda M, Tanabe N, et al. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2012;144(2):321–326. doi:10.1016/j.jtcvs.2011.09.004
   PubMed Web of Science ®Google Scholar
• Cannon JE, Su L, Kiely DG, et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort. Circulation. 2016;133(18):1761–1771. doi:10.1161/CIRCULATIONAHA.115.019470
   PubMed Web of Science ®Google Scholar
• Lang I, Meyer B, Ogo T, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160119. doi:10.1183/16000617.0119-2016
   PubMed Web of Science ®Google Scholar
• Digital, National Health Service (NHS). National audit of pulmonary hypertension. Eleventh annual report. United Kingdom: S.N.; 2021.
   Google Scholar
• Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014;43(5):1394–1402. doi:10.1183/09031936.00012914
   PubMed Web of Science ®Google Scholar
• Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24(138):621–629. doi:10.1183/16000617.0063-2015
   PubMed Web of Science ®Google Scholar
• McCollister DH, Beutz M, McLaughlin V, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010;51(4):339. doi:10.1176/appi.psy.51.4.339
   PubMed Web of Science ®Google Scholar
• Matura LA, McDonough A, Carroll DL. Health related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29(2):178–184. doi:10.1097/jcn.0b013e318275330d
   PubMed Web of Science ®Google Scholar
• Armstrong I, Billings C, Kiely DG, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med. 2019;19:67. doi:10.1186/s12890-019-0827-5
   PubMed Web of Science ®Google Scholar
• Ivarsson B, Hesselstrand R, Radegran G, Kjellstrom B. Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Chron Respir Dis. 2018;16:1–8. doi:10.1177/1479972318787906
   Web of Science ®Google Scholar
• Reis A, Santos M, Vicente M, et al. Health-related quality of life in pulmonary hypertension and its clinical correlates: a Cross-Sectional Study. Biomed Res Int. 2018;3924517:10. doi:10.1155/2018/3924517
   Google Scholar
• Kamenskaya O, Klinkova A, Chernyavskiy A, Lomivorotov VV, Edemskiy A, Shmyrev V. Long-term health-related quality of life after surgery in patients with chronic thromboembolic pulmonary hypertension. Qual Life Res. 2020;29(8):2111–2118. doi:10.1007/s11136-020-02471-z
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care Excellence. Guide to the Methods of Technolgy Appraisal. National Institute of Health and Care Excellence; 2013.
   Google Scholar
• Davies E, Llewellyn S, Beaudet A, et al. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence. 2018;12:1079–1088. doi:10.2147/PPA.S160662
   PubMed Web of Science ®Google Scholar
• Hoeper M, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. doi:10.1183/13993003.00740-2017
   PubMed Web of Science ®Google Scholar
• Darocha S, Pietura R, Pietrasik A, et al. Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J. 2017;81(4):552–557. doi:10.1253/circj.CJ-16-1075
   PubMed Web of Science ®Google Scholar
• Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary arterial hypertension patients: the long and short of it. Adv Pulm Hypertens. 2018;16(3):125–135. doi:10.21693/1933-088X-16.3.125
   Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–172. doi:10.1161/CIRCULATIONAHA.109.898122
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017
   PubMed Web of Science ®Google Scholar
• Beaudet AF. Utility Values to be Used in the Selexipag Cost-Effectiveness Model: A Pragmatic Literature Review. Actelion; 2017.
   Google Scholar
• Llewellyn S, Kosmas CE, Ballinger R, Doll H. Elicitation of Disutility Values Associated with the Mode of Administration of Drugs Acting on the Prostacyclin Pathway in Pulmonary Arterial Hypertension (PAH). Oxford, UK: ICON Plc.; 2018.
   Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690. doi:10.1038/sj.bjc.6603326
   PubMed Web of Science ®Google Scholar
• Worbes-Cerezo M, Nafees B, Lloyd A, Gallop K, Ladha I, Kerr C. Disutility study for adult patients with moderate to severe Crohn’s Disease. J Health Econ Outcomes Res. 2019;6(2):47–60. doi:10.36469/9685
   PubMedGoogle Scholar
• Statistics, Office for National. UK Data Service. Census aggregate data; 2011.
   Google Scholar
• Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62(3):374–380. doi:10.1016/j.lungcan.2008.03.019
   PubMed Web of Science ®Google Scholar
• Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin. 2010;26(5):1091–1096. doi:10.1185/03007991003712258
   PubMed Web of Science ®Google Scholar
• Janssen BMF, Oppe M, Versteegh MM, et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14(Suppl S1):S5–S13. doi:10.1007/s10198-013-0503-2
   PubMedGoogle Scholar
• Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736–741. doi:10.1136/bmj.316.7133.736
   PubMed Web of Science ®Google Scholar
• Boon G, van den Hout WB, Barco S, et al. A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. ERJ Open Res. 2021;7(3):00719–2020. doi:10.1183/23120541.00719-2020
   PubMedGoogle Scholar
• Kamenskaya O, Klinkova A, Loginova I, et al. Determinants of health-related quality of life 1 year after pulmonary thromboendarterectomy. Ann Vasc Surg. 2018;51:254–261. doi:10.1016/j.avsg.2018.02.019
   PubMed Web of Science ®Google Scholar
• European Pulmonary Hypertension Association. The Impact of Pulmonary Arterial Hypertension (PAH) on the Lives of Patients and Carers: Results from an International Survey. European Pulmonary Hypertension Association; 2012.
   Google Scholar
• Beaudet A, Davies EW, Di Scala L, et al. Association between health-related quality of life and pulmonary arterial hypertension (PAH) disease severity: a review of GRIPHON, SERAPHIN, COMPASS-2 and EARLY trials; International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual European Congress; Copenhagen, Denmark; 2019:PRO133.
   Google Scholar
• Keogh AM, McNeil K, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant. 2007;26(2):181–187. doi:10.1016/j.healun.2006.11.009
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi:10.1056/NEJMoa1503184
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi:10.1056/NEJMoa1213917
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405–413.
   PubMed Web of Science ®Google Scholar
• Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ. 2000;9(2):149–158. doi:10.1002/(SICI)1099-1050(200003)9:2<149::AID-HEC501>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Taichmann DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005;6(1):92. doi:10.1186/1465-9921-6-92
   PubMedGoogle Scholar
• Swinburn P, Shingler S, Ong SH, et al. Assessing the health-related quality of life in patients hospitalised for acute heart failure. Br J Cardiol. 2013;20:72–76.
   Google Scholar
• Hong SH, Lee JY, Park SK, et al. The utility of 5 hypothetical health states in heart failure using Time Trade-Off (TTO) and EQ-5D-5L in Korea. Clin Drug Investig. 2018;38:727–736. doi:10.1007/s40261-018-0659-8
   PubMed Web of Science ®Google Scholar
• Matza LS, Stewart KD, Lloyd AJ, et al. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812–821. doi:10.1016/j.jval.2020.12.017
   PubMed Web of Science ®Google Scholar
• Hall F, de Freitas HM, Kerr C, et al. Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28(5):1191–1199. doi:10.1007/s11136-019-02117-9
   PubMed Web of Science ®Google Scholar